Trial Profile
A trial to assess prevalence of lymphopenia in patients treated with dimethyl fumarate in a real world setting and to assess the effect of dimethyl fumarate dose reduction on lymphopenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 03 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology